荣昌生物A股盘中触及涨停

Core Viewpoint - Rongchang Biopharmaceutical (688331) experienced a significant stock price increase, reaching a peak of 16.37% on September 9, following the announcement of its innovative drug application for the treatment of Sjögren's syndrome [1] Company Summary - Rongchang Biopharmaceutical announced that its self-developed innovative drug, Tai Ta Xi Pu, which targets both BLyS and APRIL, has received formal acceptance from the National Medical Products Administration (NMPA) for its market application [1] - This drug is noted to be the first biopharmaceutical in the world to apply for market approval in the field of Sjögren's syndrome [1]